13.12
7.15%
-1.01
Vorhandelsmarkt:
13.18
0.06
+0.46%
Schlusskurs vom Vortag:
$14.13
Offen:
$14.15
24-Stunden-Volumen:
4.45M
Relative Volume:
2.12
Marktkapitalisierung:
$1.34B
Einnahmen:
$45.97M
Nettoeinkommen (Verlust:
$-508.80M
KGV:
-2.4029
EPS:
-5.46
Netto-Cashflow:
$-382.65M
1W Leistung:
-18.56%
1M Leistung:
-37.76%
6M Leistung:
-49.32%
1J Leistung:
-56.67%
Intellia Therapeutics Inc Stock (NTLA) Company Profile
Firmenname
Intellia Therapeutics Inc
Sektor
Branche
Telefon
857-285-6200
Adresse
40 ERIE STREET, CAMBRIDGE, MA
Vergleichen Sie NTLA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
NTLA | 13.12 | 1.34B | 45.97M | -508.80M | -382.65M | -5.46 |
VRTX | 451.23 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 743.35 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 591.82 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 248.79 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.14 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
2023-04-13 | Eingeleitet | Canaccord Genuity | Buy |
2023-03-21 | Eingeleitet | Bernstein | Outperform |
2023-03-14 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2023-02-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
2023-01-24 | Hochstufung | Citigroup | Sell → Neutral |
2023-01-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
2022-09-21 | Eingeleitet | JP Morgan | Overweight |
2022-09-01 | Eingeleitet | Citigroup | Sell |
2022-06-17 | Eingeleitet | BMO Capital Markets | Market Perform |
2022-06-16 | Eingeleitet | BofA Securities | Buy |
2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
2022-02-18 | Eingeleitet | William Blair | Outperform |
2022-02-07 | Hochstufung | Oppenheimer | Perform → Outperform |
2022-01-31 | Eingeleitet | Cowen | Outperform |
2022-01-07 | Eingeleitet | Piper Sandler | Overweight |
2021-10-05 | Eingeleitet | Guggenheim | Buy |
2021-09-24 | Eingeleitet | Stifel | Buy |
2021-06-28 | Bestätigt | H.C. Wainwright | Buy |
2021-06-11 | Eingeleitet | H.C. Wainwright | Buy |
2021-05-07 | Hochstufung | ROTH Capital | Neutral → Buy |
2021-05-04 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-03-04 | Eingeleitet | JMP Securities | Mkt Outperform |
2020-12-22 | Herabstufung | Robert W. Baird | Outperform → Neutral |
2020-10-27 | Eingeleitet | Truist | Buy |
2020-10-14 | Eingeleitet | Wells Fargo | Overweight |
2020-09-18 | Eingeleitet | Goldman | Buy |
2020-02-28 | Hochstufung | Oppenheimer | Perform → Outperform |
2020-02-14 | Herabstufung | Wedbush | Outperform → Neutral |
2019-11-01 | Hochstufung | Raymond James | Mkt Perform → Outperform |
2019-07-09 | Eingeleitet | Robert W. Baird | Outperform |
2019-06-10 | Eingeleitet | ROTH Capital | Neutral |
2019-05-03 | Hochstufung | Wedbush | Neutral → Outperform |
2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
2018-11-02 | Herabstufung | Wedbush | Outperform → Neutral |
2018-10-29 | Eingeleitet | Credit Suisse | Neutral |
2018-09-21 | Eingeleitet | Raymond James | Mkt Perform |
2018-05-15 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
2018-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
2017-11-01 | Bestätigt | Jefferies | Buy |
2017-06-22 | Fortgesetzt | Jefferies | Buy |
2017-03-28 | Eingeleitet | Chardan Capital Markets | Buy |
2016-08-05 | Hochstufung | Jefferies | Hold → Buy |
Alle ansehen
Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten
Equities Analysts Offer Predictions for NTLA FY2025 Earnings - MarketBeat
Intellia Therapeutics price target lowered to $55 from $76 at Barclays - MSN
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates - MSN
CF Foundation invests $15M in Recode Therapeutics to boost CF gene editing - Cystic Fibrosis News Today
Intellia Therapeutics Announces Promising CRISPR Therapy Results - Yahoo Finance
Intellia Therapeutics price target lowered to $70 from $80 at Wells Fargo - Yahoo Finance
Intellia Therapeutics' Gene Therapies Fall Short Of Breakthroughs (Rating Downgrade) - Seeking Alpha
Wells Fargo & Company Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $70.00 - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Sees Unusually-High Trading Volume Following Analyst Upgrade - MarketBeat
CRISPR therapy from Intellia may ameliorate rare heart disorder, data suggest - BioPharma Dive
Intellia Therapeutics' (NTLA) Neutral Rating Reaffirmed at Wedbush - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $91.00 at Chardan Capital - MarketBeat
Intellia stock touches 52-week low at $13.94 amid biotech slump - Investing.com
Intellia’s gene editing therapy shows early potential in rare heart condition - Clinical Trials Arena
CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy - Yahoo Finance
The Best Biotech Stocks to Buy - Morningstar
Intellia Therapeutics (NASDAQ:NTLA) Reaches New 1-Year LowHere's Why - MarketBeat
Intellia Announces First Clinical Evidence from Ongoing - GlobeNewswire
Intellia's CRISPR Therapy Shows 90%+ Disease Protein Reduction in Key Clinical Trial | NTLA Stock News - StockTitan
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Gene Editing Tools Market Size, Growth Opportunities, - openPR
Sumitomo Mitsui Trust Group Inc. Has $64.72 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (FRA:38I) Operating Income : €-492.77 Mil (TTM As of Sep. 2024) - GuruFocus.com
When (NTLA) Moves Investors should Listen - Stock Traders Daily
Intellia Therapeutics' SWOT analysis: gene editing stock's progress and potential - Investing.com India
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
3 Fast-Growing Stocks Analysts See Doubling in Price - sharewise
Oppenheimer Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $60.00 - MarketBeat
Intellia Therapeutics price target lowered to $60 from $70 at Oppenheimer - TipRanks
Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus (NASDAQ:NTLA) - Seeking Alpha
Brookline Capital Management Forecasts NTLA FY2027 Earnings - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q3 2024 Earnings Call Transcript - MSN
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at StockNews.com - MarketBeat
NTLA's Q3 Earnings & Revenues Beat Estimates, Pipeline in Focus - MSN
Intellia Therapeutics (NASDAQ:NTLA) Issues Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates - Yahoo Finance
Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day? - MSN
Intellia Earnings: Early-Stage Pipeline Makes Progress; Shares Attractive for Long-Term Investors - Morningstar
Intellia Therapeutics (NASDAQ:NTLA) Price Target Cut to $55.00 by Analysts at Barclays - MarketBeat
Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlight - GuruFocus.com
Intellia Therapeutics Inc (NTLA) Q3 2024 Earnings Call Highlights: Financial Stability and ... - Yahoo Finance Australia
ARK Investment Management LLC Buys 659,651 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics Reports Q3 2024 Financial Progress - TipRanks
Intellia Therapeutics price target lowered to $40 from $41 at JonesResearch - TipRanks
Intellia Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Intellia Therapeutics Inc earnings beat by $0.05, revenue topped estimates - Investing.com
Intellia Therapeutics reports Q3 EPS ($1.34), consensus ($1.39) - TipRanks
Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress - The Manila Times
Intellia (NTLA) Advances Phase 3 Trials Despite $135.7M Loss; $944.7M Cash Runway to 2026 | NTLA Stock News - StockTitan
Harbor Capital Advisors Inc. Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Finanzdaten der Intellia Therapeutics Inc-Aktie (NTLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Intellia Therapeutics Inc-Aktie (NTLA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Clark Eliana | EVP, Chief Technical Officer |
Jul 01 '24 |
Sale |
22.93 |
405 |
9,287 |
71,470 |
Verwiel Frank | Director |
Jun 17 '24 |
Sale |
25.00 |
1,505 |
37,625 |
17,948 |
BASTA JAMES | EVP, General Counsel |
Mar 04 '24 |
Sale |
32.99 |
2,297 |
75,778 |
81,571 |
Clark Eliana | EVP, Chief Technical Officer |
Mar 04 '24 |
Sale |
32.99 |
605 |
19,959 |
71,470 |
Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 08 '24 |
Sale |
28.87 |
2,275 |
65,682 |
43,927 |
LEONARD JOHN M | President and CEO |
Jan 03 '24 |
Sale |
29.46 |
19,223 |
566,310 |
846,486 |
Lebwohl David | EVP, Chief Medical Officer |
Jan 03 '24 |
Sale |
29.46 |
5,843 |
172,135 |
54,372 |
Sepp-Lorenzino Laura | EVP, Chief Scientific Officer |
Jan 03 '24 |
Sale |
29.46 |
5,532 |
162,973 |
46,202 |
Goddard Glenn | EVP, Chief Financial Officer |
Jan 03 '24 |
Sale |
29.46 |
5,365 |
158,053 |
40,585 |
Hicks Derek | EVP, Chief Business Officer |
Jan 03 '24 |
Sale |
29.46 |
3,877 |
114,216 |
36,987 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):